Industry concerns rise as China steps up procurement of low-cost essential drugs
This article was originally published in Scrip
The Guangdong provincial government in China is working on the final version of an essential drugs (ED) procurement programme to secure the supply of such products for the region's local community clinics. But multinationals are worried that a focus on low prices in line with a similar trial programme in another province means they will be unsuccessful in the bidding.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.